Last 7 days
-5.5%
Last 30 days
-1.6%
Last 90 days
9.5%
Trailing 12 Months
-46.8%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 298.0B | 1.4B | -3.25% | 8.54% | -148.7 | 210.43 | 20.37% | -37.45% |
ABBV | 279.9B | 58.1B | 4.88% | 1.38% | 23.64 | 4.82 | 3.30% | 2.55% |
REGN | 87.7B | 12.2B | 9.61% | 20.63% | 20.21 | 7.2 | -24.26% | -46.28% |
VRTX | 80.8B | 8.9B | 6.80% | 24.91% | 24.32 | 9.05 | 17.91% | 41.84% |
ALNY | 23.5B | 1.0B | -5.53% | 16.05% | -20.81 | 22.69 | 22.88% | -32.64% |
SRPT | 11.5B | 933.0M | 2.93% | 61.85% | -16.28 | 12.27 | 32.93% | -67.99% |
UTHR | 10.1B | 1.9B | -9.77% | 22.96% | 13.92 | 5.23 | 14.88% | 52.86% |
MID-CAP | ||||||||
MDGL | 4.2B | 504.0K | -19.59% | 144.55% | -14.38 | 2.5K | -66.53% | -22.12% |
RARE | 2.6B | 363.3M | -18.37% | -45.49% | -3.74 | 7.28 | 3.39% | -55.81% |
BPMC | 2.6B | 204.0M | 1.49% | -34.21% | -4.68 | 12.78 | 13.30% | 13.44% |
MRTX | 2.3B | 12.4M | -15.06% | -52.42% | -3.05 | 181.9 | - | -27.34% |
SMALL-CAP | ||||||||
CPRX | 1.7B | 214.2M | 4.81% | 93.98% | 20.42 | 7.92 | 52.10% | 110.42% |
MGNX | 412.2M | 151.9M | 1.98% | -27.23% | -3.44 | 2.71 | 96.19% | 40.75% |
CRBP | 28.6M | - | 145.52% | 1270.00% | -0.67 | 19.11 | -77.61% | 7.22% |
CYTK | 3.1M | 94.6M | -20.08% | -11.44% | -0.01 | 0.03 | 34.30% | -80.65% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 1.4% | 52,121,000 | 51,402,000 | 45,340,000 | 37,860,000 | 33,053,000 |
S&GA Expenses | 1.7% | 90,306,000 | 88,788,000 | 85,354,000 | 79,905,000 | 71,096,000 |
R&D Expenses | 7.4% | 419,979,000 | 391,106,000 | 354,941,000 | 323,626,000 | 229,807,000 |
EBITDA | - | -60,652,000 | - | - | - | - |
EBITDA Margin | - | -1.83 | - | - | - | - |
EBT Margin | - | -2.04 | - | - | - | - |
Net Income | -7.3% | -474,186,000 | -442,016,000 | -400,431,000 | -368,559,000 | -267,892,000 |
Net Income Margin | -5.8% | -9.10 | -8.60 | -8.83 | -9.73 | - |
Free Cahsflow | -11.7% | -346,845,000 | -310,583,000 | -297,380,000 | -264,228,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 40.2% | 1,520 | 1,084 | 1,110 | 1,203 | 1,294 |
Current Assets | 41.7% | 1,217 | 859 | 895 | 875 | 769 |
Cash Equivalents | 270.8% | 524 | 141 | 148 | 133 | 123 |
Net PPE | 5.0% | 28.00 | 27.00 | 26.00 | 24.00 | 21.00 |
Current Liabilities | -3.5% | 127 | 131 | 124 | 126 | 126 |
Shareholder's Equity | 49.8% | 1,236 | 825 | 881 | 954 | 1,040 |
Retained Earnings | -10.7% | -1,177 | -1,063 | -950 | -849 | -703 |
Additional Paid-In Capital | 27.5% | 2,420 | 1,898 | 1,841 | 1,812 | 1,746 |
Accumulated Depreciation | - | 26.00 | - | - | - | - |
Shares Outstanding | 13.7% | 87.00 | 77.00 | 76.00 | 76.00 | 74.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -11.8% | -333 | -298 | -284 | -252 | -225 |
Share Based Compensation | 12.4% | 91.00 | 81.00 | 72.00 | 59.00 | 47.00 |
Cashflow From Investing | 411.4% | 160 | 31.00 | -415 | -477 | -550 |
Cashflow From Financing | 633.5% | 583 | 79.00 | 724 | 725 | 737 |
100%
95%
72.3%
Y-axis is the maximum loss one would have experienced if Intellia Therapeutics was unfortunately bought at previous high price.
10.1%
46.0%
FIve years rolling returns for Intellia Therapeutics.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -2.06 | -562,457 | 882,543 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -23.38 | -890,000 | 815,000 | -% |
2023-02-28 | Voya Investment Management LLC | added | 2.76 | -2,192,670 | 3,910,330 | 0.01% |
2023-02-27 | Parallax Volatility Advisers, L.P. | added | 541 | 654,424 | 872,424 | -% |
2023-02-24 | NATIXIS | reduced | -8.38 | -104,930 | 133,070 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -2.34 | -492,000 | 698,000 | -% |
2023-02-16 | AXXCESS WEALTH MANAGEMENT, LLC | reduced | -21.7 | -518,469 | 494,531 | 0.04% |
2023-02-15 | Capital Impact Advisors, LLC | reduced | -10.45 | -212,503 | 373,497 | 0.36% |
2023-02-15 | Utah Retirement Systems | unchanged | - | -198,034 | 327,966 | -% |
2023-02-15 | Steward Partners Investment Advisory, LLC | reduced | -12.15 | -60,871 | 73,129 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.28% | 7,810,226 | SC 13G/A | |
Jan 25, 2023 | blackrock inc. | 8.7% | 7,254,921 | SC 13G | |
Feb 14, 2022 | nikko asset management americas, inc. | 3.70% | 2,753,903 | SC 13G/A | |
Feb 11, 2022 | regeneron pharmaceuticals, inc. | 4.98% | 3,702,995 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 10.64% | 7,916,882 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G | |
Feb 04, 2022 | sumitomo mitsui trust holdings, inc. | 3.70% | 2,753,903 | SC 13G/A | |
Feb 03, 2022 | blackrock inc. | 7.6% | 5,620,376 | SC 13G/A | |
Nov 26, 2021 | ark investment management llc | 10.40% | 7,642,452 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 0.05 -99.87% | 0.11 -99.71% | 0.32 -99.16% | 0.66 -98.28% | 0.99 -97.42% |
Current Inflation | 0.04 -99.90% | 0.10 -99.74% | 0.29 -99.24% | 0.58 -98.49% | 0.86 -97.75% |
Very High Inflation | 0.04 -99.90% | 0.09 -99.77% | 0.24 -99.37% | 0.48 -98.75% | 0.71 -98.15% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 24, 2023 | 8-K | Current Report | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 8-K | Current Report | |
Feb 23, 2023 | 10-K | Annual Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-02 | BASTA JAMES | sold | -47,741 | 43.88 | -1,088 | evp, general counsel |
2023-03-01 | Hicks Derek | acquired | - | - | 23,558 | evp, chief business officer |
2023-03-01 | Lebwohl David | acquired | - | - | 30,674 | evp, chief medical officer |
2023-03-01 | Clark Eliana | acquired | - | - | 30,673 | evp, chief technical officer |
2023-03-01 | LEONARD JOHN M | acquired | - | - | 91,036 | president and ceo |
2023-03-01 | Sepp-Lorenzino Laura | acquired | - | - | 29,938 | evp, chief scientific officer |
2023-03-01 | Goddard Glenn | acquired | - | - | 27,484 | evp, chief financial officer |
2023-03-01 | BASTA JAMES | acquired | - | - | 36,808 | evp, general counsel |
2023-01-05 | Sepp-Lorenzino Laura | sold | -89,658 | 38.4802 | -2,330 | evp, chief scientific officer |
2023-01-04 | Hicks Derek | sold | -67,424 | 37.21 | -1,812 | evp, chief business officer |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Collaboration revenue | $ 52,121 | $ 33,053 | $ 57,994 |
Type of Revenue [Extensible List] | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember |
Operating expenses: | |||
Research and development | $ 419,979 | $ 229,807 | $ 150,408 |
General and administrative | 90,306 | 71,096 | 44,169 |
Total operating expenses | 510,285 | 300,903 | 194,577 |
Operating loss | (458,164) | (267,850) | (136,583) |
Other (expense) income, net: | |||
Interest income | 8,542 | 1,283 | 2,352 |
Loss from equity method investments | (11,079) | (1,325) | 0 |
Change in fair value of contingent consideration | (13,485) | 0 | 0 |
Total other (expense) income, net | (16,022) | (42) | 2,352 |
Net loss | $ (474,186) | $ (267,892) | $ (134,231) |
Net Loss Per Share, Basic | $ (6.16) | $ (3.78) | $ (2.40) |
Net Loss Per Share, Diluted | $ (6.16) | $ (3.78) | $ (2.40) |
Weighted average shares outstanding, basic | 76,972 | 70,894 | 55,987 |
Weighted average shares outstanding, diluted | 76,972 | 70,894 | 55,987 |
Other comprehensive loss: | |||
Unrealized loss on marketable securities | $ (1,637) | $ (2,126) | $ (260) |
Other comprehensive loss from equity method investment | (3,192) | (507) | 0 |
Comprehensive loss | $ (479,015) | $ (270,525) | $ (134,491) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 523,506 | $ 123,406 |
Marketable securities | 669,116 | 625,282 |
Accounts receivable ($0.3 million and $0.1 million from related party) | 3,768 | 2,031 |
Prepaid expenses and other current assets | 20,407 | 18,584 |
Total current assets | 1,216,797 | 769,303 |
Marketable securities - noncurrent | 69,338 | 337,361 |
Property and equipment, net | 27,921 | 20,968 |
Operating lease right-of-use assets | 133,076 | 79,143 |
Equity method investment | 32,455 | 58,131 |
Investments and other assets | 40,527 | 29,558 |
Total Assets | 1,520,114 | 1,294,464 |
Current Liabilities: | ||
Accounts payable | 5,154 | 9,653 |
Accrued expenses ($1.6 million and $0 million due to related party) | 60,876 | 43,309 |
Current portion of operating lease liability | 16,685 | 9,112 |
Current portion of deferred revenue ($19.9 million and $34.2 million from related party) | 43,839 | 63,759 |
Total current liabilities | 126,554 | 125,833 |
Deferred revenue, net of current portion ($0 million and $19.9 million from related party) | 19,932 | 63,476 |
Long-term operating lease liability | 114,018 | 64,911 |
Contingent consideration liability | 24,026 | 0 |
Commitments and contingencies (Note 8) | ||
Stockholders’ Equity: | ||
Common stock, $0.0001 par value; 120,000,000 shares authorized; 87,103,007 and 74,485,883 shares issued and outstanding at December 31, 2022 and 2021, respectively | 9 | 7 |
Additional paid-in capital | 2,420,223 | 1,745,870 |
Accumulated other comprehensive income | (7,461) | (2,632) |
Accumulated deficit | (1,177,187) | (703,001) |
Total stockholders’ equity | 1,235,584 | 1,040,244 |
Total Liabilities and Stockholders’ Equity | $ 1,520,114 | $ 1,294,464 |